About
NUTEK takes part in the fight against cancer by pioneering precision in Surgical Oncology. NUTEK is addressing the problem of cancer tissues that remain undetected on the patient's body after surgical intervention, which is the main cause of subsequent cancer recurrence, repeated operations, and aggressive treatments. Furthermore, the resulting economic burden on hospitals, healthcare organizations insurance companies is significantly high.
NUTEK provides a unique intraoperative solution, the "Rainbow Probe". A high-resolution hyperspectral imaging handheld device, by which surgeons will scan the operation cavity on-the-patient’s-body during surgery. The probe guides the surgeon prior to closing, to the exact location of remaining cancer tissue, which otherwise could remain undetected, for immediate removal.
Its first application is Breast Cancer, for which the NOAM Rainbow Probe is developed, to be followed with addressing high-precision and minimally invasive, cancer surgical interventions. .
NUTEK won first prize at Paul Merage Institute startup competition and received a major non-dilutive grant from the FFG (Austrian Innovation Authority) for a two years project. NUTEK is collaborating with the Medical University of Graz in Austria and with Assuta Ashdod Hospital in Israel, completed pre-clinical experiment on breast cancer, developed MVP (TRL6) and designed critical parts of the end-product.
Funding history · 2 rounds · $1.8M total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is NUTEK OIDO's primary focus in surgical oncology?
- NUTEK OIDO focuses on pioneering precision in surgical oncology by developing an intraoperative solution for on-the-body cancer tissue detection during operations, aiming to prevent cancer recurrence caused by undetected residual tissue.
- What is the name of NUTEK OIDO's core product and its function?
- NUTEK OIDO's core product is the "Rainbow Probe," a high-resolution hyperspectral imaging handheld device. It allows surgeons to scan the operation cavity during surgery to identify and guide the removal of remaining cancer tissue.
- What was NUTEK OIDO's first application for the Rainbow Probe?
- The first application for NUTEK OIDO's Rainbow Probe, specifically the NOAM Rainbow Probe, is for breast cancer detection during surgery.
- What significant award did NUTEK OIDO receive in December 2020?
- In December 2020, NUTEK OIDO was awarded a $100,000 prize from the Paul Merage Institute's '45+ Entrepreneurs' Competition.
- Which organizations is NUTEK OIDO collaborating with for its research and development?
- NUTEK OIDO is collaborating with the Medical University of Graz in Austria and Assuta Ashdod Hospital in Israel for its research and development efforts.
- What is the current development stage of NUTEK OIDO's product?
- NUTEK OIDO has completed pre-clinical experiments on breast cancer, developed an MVP (TRL6), and designed critical parts of the end-product.
- What was the most recent grant NUTEK OIDO received from the IIA?
- NUTEK OIDO received a grant of $308,000 from the IIA in November 2023.
- What is NUTEK OIDO's total funding raised to date?
- According to startupim data, NUTEK OIDO has raised a total of $1,781,000.